U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Pfizer’s BRAFTOVI® (encorafenib) in Combination With Cetuximab to Identify Patients With BRAF V600E Alterations in Metastatic Colorectal Cancer

June 09, 2023 07:02 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx...